ARQT — ARCUTIS BIOTHERAPEUTICS INC

Ownership history in MATHER GROUP, LLC.  ·  4 quarters on record

This page tracks every 13F SEC filing in which MATHER GROUP, LLC. reported a position in ARCUTIS BIOTHERAPEUTICS INC (ARQT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 190 — 0% 0.00% $4K $18.85
2025 Q1 UNCHANGED 190 — 0% 0.00% $3K $15.64
2024 Q2 UNCHANGED 190 — 0% 0.00% $2K $9.30
2024 Q1 INITIATED 190 — — 0.00% $614 —
% of Fund (quarterly)    ARQT price (monthly, adj. close)

Other funds also holding ARQT

As of 2025 Q4 — sorted by position size

Pivotal bioVenture Partners Investment Advisor LLC 3Y 15.34% Frazier Life Sciences Management, L.P. 3Y 7.7% SUVRETTA CAPITAL MANAGEMENT, LLC 3Y 7Y 7.12% Rubric Capital Management LP 3Y 7Y 2.87% MPM BioImpact LLC 3Y 1.77% Privium Fund Management B.V. 3Y 1.64% MYDA Advisors LLC 3Y 7Y 1.47% GILDER GAGNON HOWE & CO LLC 3Y 7Y 1.37% FISHMAN JAY A LTD/MI 3Y 7Y 1.35% Patient Square Capital LP 3Y 1.31%
← Back to MATHER GROUP, LLC. Holdings